马法兰治疗骨髓增生异常综合征及其转化的急性髓系白血病临床观察

Small-dosage melphalan treatment for middle and highly-dangerous myelodysplastic syndrome and invert acute medullary system leucemia

目的观察小剂量马法兰治疗中高危骨髓增生异常综合征(MDS)及其转化的急性髓性白血病(AML)的疗效及其不良反应。方法中危II、高危MDS患者12例,MDS转化的AML患者1例,给予口服马法兰片2mg,1次/d,或2mg,两天一次,观察疗效及毒副作用。结果总有效率38.46%,其中完全缓解率7.69%;部分缓解率15.38%;血液学改善15.38%。7.69%患者发生2度骨髓抑制,其他脏器无明显损伤。结论小剂量马法兰治疗中高危骨髓增生异常综合征及其转化的急性白血病有效、服用方便。

Objective To observe the effect of small dosage-melphalan on middle and highly-dangerous myelodysplastic syndromes（MDS） and invert acute medullary system leucemia. Methods 2 mg of melphalan were used every day or every two days to treat 12 cases of middle and highly-dangerous myelodysplastic syndromes and 1 cases of invert acute medullary system leueemia. We observed the effective and side-effect.Results 1 case was relieved slightly. Total effective rate 38.46 %. Complete response was 7.69%, Partial Response was 15. 38%. Relieved slightly was 15.38%. There is no side-effect except for 7. 69% of slight marrow inhibition . Conclusion The method of small dosage-melphalan treatment on middle and highly-dangerous myelodysplastic syndrome and invert acute medullary system leucemia is safe , effective and convenient.